CD8A and breast carcinoma: In another neoadjuvant PAMELA phase II trial, 231 regions of interest (ROIs) from 129 HER2+ breast cancer patients were stained with six markers, including cytokeratin, Ki67, and four immune-related T-cell lineage markers (CD3, CD4, CD8, and Foxp3).